EWTX Key Statistics, Chart & Performance
The current stock price of EWTX is 24.9 USD. In the past month the price increased by 4.89%. In the past year, price increased by 3.11%.
EWTX Latest News, Press Relases and Analysis
EWTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About EWTX
Company Profile
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Boulder, Colorado and currently employs 136 full-time employees. The company went IPO on 2021-03-26. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The firm is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
Company Info
EDGEWISE THERAPEUTICS INC
1715 38Th St
Boulder COLORADO 80303 US
CEO: Kevin Koch
Employees: 136
Phone: 17202627002
EDGEWISE THERAPEUTICS INC / EWTX FAQ
What does EWTX do?
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Boulder, Colorado and currently employs 136 full-time employees. The company went IPO on 2021-03-26. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The firm is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
What is the stock price of EDGEWISE THERAPEUTICS INC today?
The current stock price of EWTX is 24.9 USD. The price decreased by -0.28% in the last trading session.
What is the dividend status of EDGEWISE THERAPEUTICS INC?
EWTX does not pay a dividend.
What is the ChartMill rating of EDGEWISE THERAPEUTICS INC stock?
EWTX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for EWTX stock?
EDGEWISE THERAPEUTICS INC (EWTX) currently has 136 employees.
Can you provide the market cap for EDGEWISE THERAPEUTICS INC?
EDGEWISE THERAPEUTICS INC (EWTX) has a market capitalization of 2.64B USD. This makes EWTX a Mid Cap stock.
Can you provide the ownership details for EWTX stock?
You can find the ownership structure of EDGEWISE THERAPEUTICS INC (EWTX) on the Ownership tab.
EWTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to EWTX. When comparing the yearly performance of all stocks, EWTX is one of the better performing stocks in the market, outperforming 88.22% of all stocks.
EWTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EWTX. EWTX has a great financial health rating, but its profitability evaluates not so good.
EWTX Financial Highlights
Over the last trailing twelve months EWTX reported a non-GAAP Earnings per Share(EPS) of -1.58. The EPS decreased by -5.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.95% | ||
| ROE | -28.15% | ||
| Debt/Equity | 0 |
EWTX Forecast & Estimates
18 analysts have analysed EWTX and the average price target is 38.93 USD. This implies a price increase of 56.35% is expected in the next year compared to the current price of 24.9.